Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based Platform

Purpose: This study aimed to construct a novel platform for the detection of circulating tumor cells (CTC) in patients with hepatocellular carcinoma (HCC) and to investigate the clinical significance of epithelial cell adhesion molecule mRNA-positive (EpCAMmRNA+) CTCs using this platform. Experimental Design: An optimized platform for CTC detection was constructed by evaluating different negative enrichment, mRNA isolation, and cDNA synthesis procedures and compared with the CellSearch system. A total of 299 patients with HCC were recruited into this prospective study; of these, 157 who received curative resection, 76 who received transcatheter arterial chemoembolization (TACE), and 66 who received radiotherapy were tested using our platform. The diagnostic value of EpCAMmRNA+ CTCs was investigated in 122 patients with HCC who underwent resection and 120 control subjects. Results: The optimized negative enrichment and quantitative real-time PCR (qRT-PCR)-based CTC detection platform had high sensitivity, specificity, and reproducibility and a low sample volume requirement. This platform showed a potential diagnostic value in patients with HCC and exhibited 76.7% consistency with the CellSearch system (r = 0.54, P < 0.050). Pretreatment CTC level showed prognostic significance in patients with HCC treated with resection, TACE, and radiotherapy (all P < 0.050). Most of the patients showed a decrease in CTC levels after treatment that reflected tumor response. In contrast, patients with an increased CTC level showed disease progression after treatment. Conclusions: We established an optimized platform based on negative enrichment and qRT-PCR for highly sensitive, specific, and reproducible CTC detection. This platform might be clinically useful in auxiliary diagnosis, treatment response assessment, and early decision-making to tailor the most effective antitumor strategies. Clin Cancer Res; 20(18); 4794–805. ©2014 AACR.

[1]  Younghee Lee,et al.  Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. , 2014, Cancer research.

[2]  Klaus Pantel,et al.  [The circulating tumor cells: liquid biopsy of cancer]. , 2014, Klinicheskaia laboratornaia diagnostika.

[3]  K. Pantel,et al.  Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma , 2013, International journal of cancer.

[4]  E. Song,et al.  Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Pantel,et al.  Real-time liquid biopsy in cancer patients: fact or fiction? , 2013, Cancer research.

[6]  K. Pantel,et al.  Capture of viable circulating tumor cells in the liver of colorectal cancer patients. , 2013, Clinical chemistry.

[7]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[8]  W. Guo,et al.  Circulating stem cell–like epithelial cell adhesion molecule–positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection , 2013, Hepatology.

[9]  S. Miyano,et al.  Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. , 2013, Cancer research.

[10]  X. Wang,et al.  Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma , 2013, Hepatology.

[11]  G. Giaccone,et al.  Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[12]  Caroline Dive,et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jeffrey E. Lee,et al.  Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma , 2012, Annals of surgery.

[14]  Zheng Wang,et al.  Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Perez,et al.  Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437 , 2011, Clinical Cancer Research.

[16]  Jaap M J den Toonder,et al.  Circulating tumor cell isolation and diagnostics: toward routine clinical use. , 2011, Cancer research.

[17]  Jia Fan,et al.  Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance , 2011, Journal of Cancer Research and Clinical Oncology.

[18]  L. V. van't Veer,et al.  A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer , 2011, British Journal of Cancer.

[19]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Mitsuru Sasako,et al.  Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  John W M Martens,et al.  mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients , 2011, Clinical Cancer Research.

[22]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[23]  E. Lianidou,et al.  Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. , 2011, Clinical chemistry.

[24]  S. Qiu,et al.  High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma , 2010, Gut.

[25]  S. Braun,et al.  Circulating tumor cells revisited. , 2010, JAMA.

[26]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[27]  Anne-Michelle Noone,et al.  Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Stephanie Roessler,et al.  MicroRNA expression, survival, and response to interferon in liver cancer. , 2009, The New England journal of medicine.

[29]  D. Mavroudis,et al.  Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[31]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Zhi-quan Wu,et al.  Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection , 2008, Clinical Cancer Research.

[33]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[34]  G. Kallergi,et al.  Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer , 2008, Clinical Cancer Research.

[35]  A. Jimeno,et al.  Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[37]  M. Dowsett,et al.  Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques , 2005, British Journal of Cancer.

[38]  S. Fan,et al.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E. Lianidou,et al.  SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. , 2013, Clinical chemistry.

[40]  J. Izbicki,et al.  Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. , 2013, Clinical chemistry.

[41]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[42]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[43]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[44]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.